FGFR3 Mutations in Epidermal Nevi and Seborrheic Keratoses: Lessons from Urothelium and Skin  by Hafner, Christian et al.
COMMENTARY
1572 Journal of Investigative Dermatology (2007), Volume 127
See related article on pg 1664
FGFR3 Mutations in Epidermal Nevi 
and Seborrheic Keratoses: Lessons 
from Urothelium and Skin
Christian Hafner1, Arndt Hartmann2, and Thomas Vogt1
Somatic FGFR3 mutations have been reported in various cancers such as urothe-
lial carcinoma. Evidence is growing that these mutations are also involved in the 
pathogenesis of benign acanthotic skin tumors such as epidermal nevi and sebor-
rheic keratoses. The report by Hernandez et al. strongly supports this concept. 
However, further studies are required for a better pathogenetic understanding of 
FGFR3 related tumors in urothelium and skin.
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Germline mutations of the FGFR3 gene 
cause well-known skeletal dysplasia syn-
dromes such as achondroplasia, hypo-
chondroplasia, thanatophoric dysplasia, 
severe achondroplasia with develop-
mental delay and acanthosis nigricans 
(SADDAN) syndrome, and Crouzon 
syndrome. Somatic FGFR3 mutations 
have been identified in several cancers 
such as urothelial cancer and multiple 
myeloma (L’Hote and Knowles, 2005).
Some skeletal dysplasia syndromes 
(e.g., thanatophoric dysplasia and 
SADDAN syndrome) are associated 
with the development of papillomatous 
brownish skin lesions termed acantho-
sis nigricans (AN). AN, epidermal nevi 
(EN), and seborrheic keratoses (SK) 
share many histopathological features, 
including acanthosis, papillomatosis, 
hyperkeratosis, and hyperpigmentation. 
This observation suggests a potential 
involvement of FGFR3 mutations in the 
pathogenesis of benign acanthotic skin 
tumors such as EN and SK. Furthermore, 
some patients with EN developed a uro-
thelial carcinoma at an unusually early 
age, also suggesting a potential role of 
FGFR3 mutations in both entities. Logie 
et al. (2005) demonstrated that somatic 
FGFR3 mutations in fact are important 
for the development of SK. Transgenic 
mice expressing a mutant FGFR3 recep-
tor (S249C) in the epidermis devel-
oped verrucous skin lesions closely 
resembling human SK histologically. 
The authors subsequently screened a 
series of human SK and identified acti-
vating FGFR3 mutations in 39% of the 
lesions. Normal skin of these patients 
did show a wild-type FGFR3 sequence, 
confirming the somatic nature of these 
mutations. Another study found FGFR3 
mutations in 85% of adenoid SK, a spe-
cial histological subtype of SK (Hafner 
et al., 2006a).
Activating FGFR3 mutations were 
also identified in 33% of patients with 
common non-organoid keratinocytic 
EN (Hafner et al., 2006b). The muta-
tions were present only in the EN, 
which follow the lines of Blaschko, 
while adjacent normal skin showed a 
wild-type FGFR3 sequence. Therefore, 
a considerable proportion of com-
mon non-organoid EN are caused 
by a mosaicism of the FGFR3 gene in 
human skin. The study of Hernández 
et al. (2007, this issue) strongly con-
firms these previous results. The authors 
detected FGFR3 mutations in 26% of 
the investigated EN. Interestingly, both 
studies found almost exclusively the 
R248C mutation, which appears to be 
an important hot spot in EN. In addi-
tion to sequence analysis, the authors 
performed immunohistochemistry for 
FGFR3 protein in the EN. In contrast to 
urothelial carcinoma, no overexpres-
sion of FGFR3 protein was observed in 
the EN.
Although previous data suggested 
that FGFR3 mutations could be the 
common genetic basis in patients with 
EN and urothelial carcinoma, unex-
pectedly neither the bladder tumors 
nor the EN displayed any FGFR3 muta-
tions in two investigated patients. The 
authors conclude that other genes are 
involved in the tumorigenesis of both 
urothelial carcinoma and EN in these 
patients. Furthermore, the possibility 
remains that other FGFR3 mutations in 
exons that have not yet been analyzed 
contribute to EN.
It is striking that only a few muta-
tional hot spots account for all FGFR3 
mutations detected in urothelial car-
cinomas and skin tumors (EN and SK) 
so far. Most of these mutations are 
associated with thanatophoric dyspla-
sia, SADDAN syndrome, or Crouzon 
syndrome in germline. In contrast, the 
G1144A mutation, which is the most 
frequent mutation in achondroplasia 
and probably one of the most frequent 
mutations in the human genome at all, 
was not identified as a single muta-
tion in EN and SK in previous studies 
(Hafner et al., 2006c). Thanatophoric 
dysplasia and SADDAN syndrome are 
characterized by a severe phenotype, 
which correlates well with a strong 
activation of the receptor (Naski et al., 
1996). Interestingly, these skeletal dys-
plasias are associated with AN of the 
skin, while achondroplasia and hypo-
chondroplasia patients show a less 
severe phenotype and usually do not 
develop AN of their skin. We therefore 
hypothesize that the development of 
benign acanthotic tumors in the epider-
mis requires a strong degree of FGFR3 
activation. Only FGFR3 mutations asso-
ciated with severe skeletal dysplasia 
syndromes obviously provide a selec-
tive growth or survival advantage to the 
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mutated keratinocytes (Hafner et al., 
2006c), but further studies are required 
to prove this hypothesis.
The mechanisms causing FGFR3 
mutations in urothelium and epider-
mis are as yet unknown. Although 
the R248C mutation, one of the most 
frequent mutations in EN and SK, rep-
resents a C→T transition at a dipy-
rimidine site referred to as a typical 
UV-signature mutation, a causative 
role of UV light is not likely in EN 
because the mutations are thought to 
occur during embryogenesis in epi-
dermal stem cells. In human SK, the 
R248C mutation might be associated 
with UV light, because epidemiologic 
studies have suggested that UV light 
exposure is an independent risk fac-
tor for the development of SK (Kwon 
et al., 2003). However, other FGFR3 
mutations detected in these skin 
lesions have no UV signature, and in 
urothelium UV light exposure can be 
excluded. Exogenous carcinogens did 
not induce FGFR3 mutations in animal 
models of bladder cancer (Dunois-
Larde et al., 2005). Because the fre-
quency of FGFR3 germline mutations 
correlates with advanced paternal age 
and the incidence of SK increases with 
age, FGFR3 mutations might be associ-
ated with an accumulation of replica-
tive errors in the DNA, but this remains 
speculative. Likewise, details of the 
involved signaling pathways in FGFR3 
mutant urothelial and epidermal cells 
are only marginally known (L’Hote 
and Knowles, 2005). Aberrant FGFR3 
signaling appears to be cell-type spe-
cific and might mediate the growth of 
benign tumors by enhanced prolifera-
tion, resistance to apoptosis, or induc-
tion of senescence.
Because FGFR3 mutations obvi-
ously do not account for all papillary 
urothelial cancers and acanthotic skin 
tumors, further genes must be involved 
in tumorigenesis. Members of the path-
ways downstream of FGFR3 such as the 
PI-3K/PTEN/Akt or the Ras/Raf/MAPK 
pathway are promising candidates, 
as well as alterations of the PTCH and 
TSC1 genes as suggested by Hernández 
et al. (2007). As yet unknown addi-
tional mutations in these genes might 
also determine the histologic subtypes 
of acanthotic skin tumors. Three major 
histologic subtypes of SK are known 
(hyperkeratotic, acanthotic, and ade-
noid SK). However, the spectrum of 
FGFR3 mutations did not correlate 
with the SK subtypes. Likewise, nei-
ther Hernández et al. (2007) nor our 
previous study found a significant cor-
relation between the FGFR3 mutational 
spectrum and the histological subtypes 
of EN. It remains elusive why patients 
with FGFR3 germline mutations, e.g., 
in SADDAN and Crouzon syndrome, 
develop concomitant AN preferentially 
in intertriginous areas, although the 
underlying FGFR3 mutation is present 
in the entire skin. This suggests a pos-
sible contribution of as yet unknown 
local or environmental factors.
Interestingly, in urothelial cancer 
FGFR3 mutations correlate with papil-
lary tumors, and these patients have 
a better prognosis than patients with 
FGFR3 wild-type tumors (Hernandez 
et al., 2006). This is congruent with the 
benign behavior of epidermal nevi and 
seborrheic keratoses, in which malig-
nant transformation has been reported 
only very exceptionally. The previous 
data suggest that FGFR3 mutations 
obviously induce the controlled and 
limited growth of benign tumors in epi-
thelial cells without a metastatic poten-
tial. They seem to be an early genetic 
event, at least in the urinary bladder, 
because they are found in precursor 
lesions of papillary tumors such as uro-
thelial hyperplasias (van Oers et al., 
2006). We agree with Hernández et al. 
(2007) that the comparison of benign 
epithelial tumors in urothelium and 
skin with their malignant counterparts 
could provide promising new insights 
in tumor development and progression.
Apart from a better pathogenet-
ic understanding of acanthotic skin 
tumors, the investigation of FGFR3 
mutations might also provide new 
therapeutic strategies for the treatment 
of these skin lesions. Epidermal nevi 
and seborrheic keratoses are currently 
removed surgically. Because specific 
small-molecule inhibitors of FGFR3 are 
already available and currently undergo 
evaluation in clinical studies for the sys-
temic treatment of malignancies such as 
leukemia, a topical application of these 
drugs seems possible for noninvasive 
treatment of acanthotic skin tumors.
Future studies are required to better 
define the meaning and pathophysi-
ological consequences of FGFR3 muta-
tions in the epithelium of bladder and 
skin. These studies should provide an 
answer to the provocative hypothesis 
that papillary urothelial tumors repre-
sent the “seborrheic keratoses of the 
bladder.”
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